Navigation Links
EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation

AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.

"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The EMEA's orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in the European Union and for which no satisfactory therapy is available. The orphan drug designation provides for incentives to support research and development, exemption from user fees and a ten-year period of market exclusivity in the European Union after product approval.

For the complete press release please go to:

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit '/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
(Date:10/9/2015)... and ROCKVILLE, Md. ... ("ITI"), a privately-held biotechnology company developing next generation ... that it has entered into an exclusive worldwide ... products for the treatment or prevention of any ... of the agreement, Immunomic Therapeutics will receive an ...
(Date:10/9/2015)... ... October 09, 2015 , ... Leading microbial genomics startup uBiome today launched the ... relationship between weight management and the microbiome. The study uses the ResearchKit framework, designed ... iPhone app. , The uBiome app is available as a free download from the ...
(Date:10/8/2015)... 2015  Genetic testing for mutations beyond those currently ... more couples at risk of having a child with ... the 2015 American Society of Human Genetics (ASHG) Annual ... Baltimore, Maryland . The study is one of ... ) are presenting at the conference this week demonstrating ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
Breaking Biology Technology:
... Switzerland, Nov. 16, 2010 Syngenta has announced the ... from Australia, Zoltan Balogh from Hungary and Mario Pereda ... vouchers of $8000, $5000 and $3000, respectively. The winning ... based upon their quality, creativity and interpretation of Syngenta,s ...
... Nov. 16, 2010 Ingenuity® Systems, a ... science researchers, today announced a new collaboration ... predictive disease network research.  Under the collaboration, ... software, and the Ingenuity® Knowledge Base of ...
... 15, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: ... biotechnology company focused on researching, developing, manufacturing and marketing ... the third quarter ended September 30, 2010. ... Total net revenues increased by 24.9% over ...
Cached Biology Technology:
(Date:10/8/2015)... , 8. Oktober 2015 ... global tätiges Unternehmen des Bereiches Tracking, hat ... mit der Gefängnisbehörde Virginias (Department of Corrections ... elektronische Überwachungsdienste für alle Strafen geliefert werden, ... Cassell , Präsident für den Amerikanischen Kontinent ...
(Date:10/7/2015)... 8, 2015 --> ... Cards (FPC) during third quarter 2015 amounted to around 960 ... 860 MSEK that was communicated 20 August 2015. ... delivery capacity and a continued growing demand for the company,s ... to be higher than during the third quarter. The revenue ...
(Date:10/6/2015)... Oct. 6, 2015 Track Group, Inc. (OTCQX: ... it has signed a contract with the Virginia Department ... full range of sentences under the Department,s oversight. ... Americas. "This contract with the Virginia DOC will expand ... and advances our position as a trusted leader in ...
Breaking Biology News(10 mins):
... commends President George W. Bush for asking Congress to ... physical sciences in his State of the Union address ... how paramount funding into basic research is to keeping ... Russ Lefevre said. "Much of our nations economic growth ...
... of complex, three-dimensional nanoscale structures and the ability ... now possible with a process developed by researchers ... the rapid evaporation of solvent from simple inks, ... nanofibers, stacked arrays of nanofibers and continuously wound ...
... Journeying to Johannesburg to survey bat colonies? To Kenya to ... about Roman ruins in Britain? Snowflakes in North America? ... an entire digital database of weird and wacky but ... matter. And that includes French cheese, purposeful knots and English ...
Cached Biology News: